Mast cell chymase and tryptase during tissue turnover: analysis on in vitro mitogenesis of fibroblasts and keratinocytes and alterations in cutaneous scars.
In order to shed further light on the potential role of mast cells during tissue turnover, we have investigated the number of mast cells containing only tryptase and those storing both tryptase and chymase by enzyme histochemistry in normal versus healing skin. Furthermore, we have studied the in vitro effect of these enzymes on the mitogenesis of subconfluent quiescent fibroblast and HaCaT keratinocyte cultures, using flowcytometric DNA analysis. Chymase-containing mast cell numbers were markedly decreased in scars (P<0.001), whereas the overall number of tryptase-containing mast cells was not decreased, although these cells were smaller and stained more faintly in scars. Chymase (5 to 300 mU/ml) induced a marked, dose-dependent in vitro mitogenic response in 3T3 fibroblasts, whereas the effects of tryptase, at up to 60 nM, were only moderate, compared to the known fibroblast mitogens EGF, TGF-alpha, alpha-thrombin and trypsin at optimal concentrations. Coincubation of either protease with EGF or alpha-thrombin had additive effects. In contrast to fibroblasts, keratinocytes showed only minor mitogenic responses to tryptase and chymase, also in comparison to other known mitogenic stimuli, and responses to EGF and alpha-thrombin were inhibited on costimulation of cells with the proteases. These findings document for the first time a potential role of mast cell chymase in connective tissue repair, with tryptase being less active on fibroblasts, and with inhibitory effects of both mast cell proteases on keratinocytes.
Algermissen
B
B
Department of Dermatology, Charité-Virchow Clinic, Humboldt University, Berlin, Germany.
Hermes
B
B
Feldmann-Boeddeker
I
I
Bauer
F
F
Henz
B M
BM
D016475:3T3 Cells; D000818:Animals; D002452:Cell Count; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D053818:Chymases; D002921:Cicatrix / Q000201:enzymology / Q000473:pathology; D003238:Connective Tissue / Q000201:enzymology / Q000378:metabolism*; D003470:Culture Media / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004815:Epidermal Growth Factor / Q000494:pharmacology; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D015603:Keratinocytes / Q000166:cytology / Q000187:drug effects / Q000201:enzymology; D008407:Mast Cells / Q000166:cytology / Q000201:enzymology*; D051379:Mice; D008934:Mitogens / Q000494:pharmacology; D008938:Mitosis / Q000187:drug effects; D012697:Serine Endopeptidases / Q000378:metabolism* / Q000494:pharmacology; D012867:Skin / Q000166:cytology / Q000187:drug effects / Q000201:enzymology; D016211:Transforming Growth Factor alpha / Q000494:pharmacology; D053802:Tryptases
D003470:Culture Media; D008934:Mitogens; C509190:Tpsb2 protein, mouse; D016211:Transforming Growth Factor alpha; D004815:Epidermal Growth Factor; D012697:Serine Endopeptidases; C083294:chymase 2; D053818:Chymases; C509229:Cma2 protein, mouse; C509222:Tpsab1 protein, mouse; D053802:Tryptases